The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics
UF startup Dialectic Therapeutics, in partnership with the Fibrolamellar Cancer Foundation (FCF), will supply the experimental drug DT2216 for a clinical trial involving fibrolamellar patients.
Researchers and UF Innovate | Accelerate startup founders find Highly Effective Therapeutic Strategy for Small-Cell Lung Cancer
The proteins BCL-XL and BCL-2 can be targeted to help treat small-cell lung cancer (SCLC), a team of researchers has found. Previous treatments targeted these proteins using navitoclax, an anti-cancer drug, which resulted in platelet toxicity.
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation From the FDA for the Treatment of T-Cell Lymphoma
UF startup Dialectic Therapeutics, Inc. (Dialectic®), announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DT2216 for the treatment of T-cell lymphoma.
Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, Its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients With Relapsed or Refractory Malignancies
UF startup Dialectic Therapeutics, Inc., a Texas-based clinical-stage biotechnology company focused on creating innovative new technologies to treat cancer, announced the dosing of the first patient in a first-in-human, dose-escalation Phase 1 trial evaluating DT2216, the first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology, in patients with relapsed or refractory solid tumor and hematologic malignancies.
Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer
UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology.
